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Editorial 
Hepatitis B virus (HBV) infection is one of the major human health problems worldwide.  It is estimated that 
chronic HBV infection affects more than 350 million people globally, spreading in every continent in Asia, America,  
Europe, and Africa. Despite the huge number of HBV infected cases, it has not received enough attention as it should be 
i n  t e r m  o f  r e s e a r c h  f u n d i n g  a n d  m e d i a  c o v e r a g e .  I n  t h e  p a s t  f e w  y e a r s ,  s i g n i f i c a n t  a d v a n c e s  h a v e  b e e n  m a d e  i n  
molecular virology, pathogenesis and treatment of HBV infection. However, there still exist many challenges in HBV 
research, clinical management, and exploration of safe and effective therapies for chronic hepatitis B. 
This special issue intends to provide a broad view and the update advances in HBV research from basic science to 
clinic management of HBV infection. For basic scientific research, two articles were selected focusing on topics involved 
in HBeAg mutant and its clinical implication, and the association of altered apoptosis with HBV infection and 
development of HCC.  For clinical advances, six articles were selected focusing on molecular diagnosis, approaches for 
management of chronic HBV infection, immunomodulating therapy, liver transplantation, HBV  epidemiology and 
prevention, and natural history.  Since chronic HBV infection has different clinical presentation which needs a different 
approach to management, three of the six articles address the general principle of HBV management, immunotherapy, 
and liver transplant in HBV infected patients.   
Topics in this issue touch important progresses of current HBV study.  Authors have provided their expertise for 
the prospective research in the future, and we hope this will inspire the efforts on understanding, treating, and 
eventually eradicating the existence of HBV infection in Human. 
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